Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX

Akero Therapeutics, Inc. acquired by Novo Nordisk for up to $5.2 billion, driven by strong phase 2b results for EFX. Read ...
pharmaphorum

EMA panel endorses AI for MASH clinical trials

Screenshot of PathAI's AIM-MASH AI Assist in action. An artificial intelligence model developed by PathAI – used to help diagnose metabolic dysfunction associated steatohepatitis (MASH) from liver ...
pharmaphorum

Boehringer’s survodutide shows monster MASH potential

Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the results of a mid-stage trial are ...
PC Magazine

The Best Adobe Photoshop Alternatives for 2025

I’ve been writing and editing technology articles for more than seven years, most recently as part of PCMag's software team. I am responsible for content in the AI, financial, graphic design, ...
Reuters

Healthcare & Pharmaceuticals

Britain's King Charles greets people during a visit to mark the 150th anniversary of the Albert Hall in Ballater, Scotland, Britain, October 9, 2025. Jane Barlow/Pool via REUTERS Britain's King ...